ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
건선 바이오시밀러 시장 규모는 최근 급성장하고 있습니다. 2025년 81억 6,000만 달러에서 2026년에는 90억 8,000만 달러에 이르고, CAGR 11.3%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 참조 생물학적 제제의 높은 비용, 환자의 치료 접근성 제한, 중등도에서 중증의 건선 환자 증가, 의사의 인식 개선 및 처방 증가, TNF-α 억제제의 초기 승인 등이 주요 요인으로 작용한 것으로 보입니다.
건선 바이오시밀러 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 137억 9,000만 달러에 이르고, CAGR은 11.0%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 인플릭시맙, 에타너셉트, 아달리무맙의 신규 바이오시밀러 출시, 병원 및 온라인 약국 네트워크 확대, 피부과 의료비 증가, 환자 지원 프로그램 도입 확대, 신규 바이오시밀러 임상시험 증가 등을 꼽을 수 있습니다. 등이 있습니다. 예측 기간 동안 주요 동향으로는 비용 효율적인 건선 바이오시밀러의 채택 확대, 환자 접근성 및 경제성에 대한 관심 증가, 피하 및 정맥 투여 경로의 성장, 병원 및 소매 약국 유통 채널의 확대, 다양한 건선 유형에 대한 표적 치료법 개발 등이 있습니다.
건선성 관절염의 진단율 증가는 건선 바이오시밀러 시장을 견인할 것으로 예측됩니다. 건선성 관절염은 관절과 피부가 붓는 지속적인 자가면역질환으로, 건선 병력이 있는 사람에게서 많이 나타납니다. 특히 건선 환자의 정밀 검진을 통해 기존에 간과하기 쉬웠던 초기 미묘한 관절 증상을 조기에 포착할 수 있게 되면서 진단율이 높아지고 있습니다. 건선 바이오시밀러는 합리적인 가격의 생물학적 제제 대체품으로 건선성 관절염을 완화하고 관절의 염증 발작과 피부 증상을 억제합니다. 예를 들어, 2025년 8월 미국 환자 지원 비영리단체인 전미건선재단(NPF)은 건선 환자 약 3명 중 1명이 건선성 관절염을 앓고 있으며, 240만 명의 미국인이 건선성 관절염을 앓고 있다고 발표한 바 있습니다. 건선 환자의 15% 이상이 진단되지 않은 건선성 관절염을 가지고 있어, 진단의 격차 속에서 더 나은 진단의 필요성이 강조되고 있습니다. 이처럼 건선성 관절염 진단 건수 증가가 건선 바이오시밀러 시장을 견인하고 있습니다.
건선 바이오시밀러 시장을 선도하는 기업들은 플라크형 건선용 바이오시밀러 등 새로운 옵션을 개발하여 치료 접근성 확대, 비용 절감, 치료 효과 향상을 위해 노력하고 있습니다. 심상성 건선 바이오시밀러는 붉은 비늘을 동반한 피부 자가면역질환을 치료하는 레퍼런스 생물학적 제제와 거의 동등한 수준의 경제적인 대안을 제공합니다. 예를 들어, 2025년 5월 스위스의 제네릭 의약품 및 바이오시밀러 전문 기업 샌드그룹(Sand Group AG)은 최초의 시판용 우스테키누맙 바이오시밀러 자동 주사기 'Pyzchiva'를 출시했습니다. 본 제품은 성인 플라크형 건선, 건선성 관절염, 크론병, 성인용 플라크형 건선뿐만 아니라 6세 이상(체중 60kg 이상) 소아 플라크형 건선 환자에게도 적응증을 인정받았으며, 정확한 자동투여, 통증 완화, 슬림한 형태, 간편한 보관으로 번거로움 없는 자가투여를 실현하여 복약순응도와 삶의 질을 향상시킵니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Psoriasis biosimilars are biologic drugs developed to closely replicate the structure, function, safety, and efficacy of approved reference biologics for treating moderate to severe psoriasis. These biosimilars offer a more affordable alternative to original biologics, increasing patient access to advanced therapies without compromising quality or clinical outcomes.
The main drug classes in psoriasis biosimilars include TNF-alpha inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are biologics that block tumor necrosis factor-alpha (TNF-a), a key protein driving inflammation in psoriasis. They are used to treat various forms of psoriasis, including plaque, guttate, inverse, and pustular psoriasis, and are administered via subcutaneous, intravenous, oral, and topical routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have impacted the psoriasis biosimilars market by increasing the cost of imported biologics, reference molecules, and active pharmaceutical ingredients. Hospital pharmacies and retail distribution channels in regions like North America and Europe, which depend on imports, are most affected. This has led to higher treatment costs and potential delays in patient access. On the positive side, tariffs have encouraged local manufacturing, boosted investment in domestic biosimilar production, and promoted innovation in cost-effective psoriasis therapies.
The psoriasis biosimilars market research report is one of a series of new reports from The Business Research Company that provides psoriasis biosimilars market statistics, including psoriasis biosimilars industry global market size, regional shares, competitors with a psoriasis biosimilars market share, detailed psoriasis biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. This psoriasis biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $8.16 billion in 2025 to $9.08 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to high cost of reference biologics, limited patient access to treatment, growing prevalence of moderate to severe psoriasis, increasing physician awareness and prescriptions, initial approvals of TNF-alpha inhibitors.
The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $13.79 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to launch of new biosimilars for infliximab, etanercept, and adalimumab, expansion of hospital and online pharmacy networks, increasing healthcare expenditure on dermatology, rising adoption of patient assistance programs, growth in clinical trials for novel biosimilars. Major trends in the forecast period include rising adoption of cost-effective psoriasis biosimilars, increased focus on patient access and affordability, growth in subcutaneous and intravenous administration routes, expansion of hospital and retail pharmacy distribution channels, development of targeted therapies for different psoriasis types.
The climbing psoriatic arthritis diagnosis rates are poised to drive the psoriasis biosimilars market forward. Psoriatic arthritis is a persistent autoimmune disorder sparking joint and skin swelling, commonly in those with psoriasis backgrounds. Diagnosis rates are up, especially from refined screening in psoriasis patients that catches early, faint joint signs once overlooked. Psoriasis biosimilars ease psoriatic arthritis with budget-friendly biologic stand-ins, curbing joint flare-ups and skin issues. For example, in August 2025, the National Psoriasis Foundation (NPF), a US patient advocacy non-profit, stated psoriatic arthritis hits about 1 in 3 psoriasis cases, impacting 2.4 million Americans; over 15% of psoriasis sufferers have undetected psoriatic arthritis, underscoring better detection amid gaps. Thus, the rising psoriatic arthritis diagnoses are fueling the psoriasis biosimilars market.
Leading firms in the psoriasis biosimilars market are rolling out fresh options like biosimilars for plaque psoriasis to widen access, trim expenses, and lift results. Biosimilars for plaque psoriasis offer economical, near-identical swaps for reference biologics tackling the ongoing skin autoimmune issue with red, flaky patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based generics and biosimilars specialist, debuted the Pyzchiva autoinjector-the inaugural commercial ustekinumab biosimilar auto-device. Approved for adult plaque psoriasis, psoriatic arthritis, and Crohn's, plus kids over six (60+ kg) with plaque psoriasis, it boosts compliance and life quality via precise auto-dosing, less pain, slim profile, and easy storage for hassle-free self-use.
In September 2023, Sandoz Group AG, a Switzerland pharma player, teamed with Samsung Bioepis to market the SB17 (ustekinumab) biosimilar. This alliance taps both strengths to deliver the plaque psoriasis treatment across Europe and North America. It broadens reach to quality, affordable immunology care, cementing Sandoz's biosimilars dominance. Samsung Bioepis is a South Korea biopharma focused on biosimilars, including plaque psoriasis therapies.
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.
North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the psoriasis biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Psoriasis Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses psoriasis biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for psoriasis biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The psoriasis biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: TNF-Alpha Inhibitors; Infliximab; Etanercept; Adalimumab; Other Biosimilars
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Cost-Effective Psoriasis Biosimilars
4.2.2 Increased Focus On Patient Access And Affordability
4.2.3 Growth In Subcutaneous And Intravenous Administration Routes
4.2.4 Expansion Of Hospital And Retail Pharmacy Distribution Channels
4.2.5 Development Of Targeted Therapies For Different Psoriasis Types
5. Psoriasis Biosimilars Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Retail Pharmacies
5.3 Online Pharmacies
5.4 Dermatology Clinics
5.5 Specialty Care Centers
6. Psoriasis Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Psoriasis Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Psoriasis Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Psoriasis Biosimilars Market Size, Comparisons And Growth Rate Analysis
7.3. Global Psoriasis Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Psoriasis Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Psoriasis Biosimilars Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Psoriasis Biosimilars Market Segmentation
9.1. Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
9.2. Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.5. Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
9.6. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Remicade Biosimilars, CT-P13 Biosimilars
9.7. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Enbrel Biosimilars, SB4 Biosimilars
9.8. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Humira Biosimilars, ABP 501 Biosimilars
9.9. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ustekinumab Biosimilars, Secukinumab Biosimilars
10. Psoriasis Biosimilars Market Regional And Country Analysis
10.1. Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Psoriasis Biosimilars Market
12.1. China Psoriasis Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Psoriasis Biosimilars Market
13.1. India Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Psoriasis Biosimilars Market
14.1. Japan Psoriasis Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Psoriasis Biosimilars Market
15.1. Australia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Psoriasis Biosimilars Market
16.1. Indonesia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Psoriasis Biosimilars Market
17.1. South Korea Psoriasis Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Psoriasis Biosimilars Market
19.1. South East Asia Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Psoriasis Biosimilars Market
20.1. Western Europe Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Psoriasis Biosimilars Market
21.1. UK Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Psoriasis Biosimilars Market
22.1. Germany Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Psoriasis Biosimilars Market
23.1. France Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Psoriasis Biosimilars Market
24.1. Italy Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Psoriasis Biosimilars Market
25.1. Spain Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Psoriasis Biosimilars Market
26.1. Eastern Europe Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Psoriasis Biosimilars Market
27.1. Russia Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Psoriasis Biosimilars Market
28.1. North America Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Psoriasis Biosimilars Market
29.1. USA Psoriasis Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Psoriasis Biosimilars Market
31.1. South America Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Psoriasis Biosimilars Market
32.1. Brazil Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Psoriasis Biosimilars Market
33.1. Middle East Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Psoriasis Biosimilars Market
34.1. Africa Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Psoriasis Biosimilars Market, Segmentation By Drug Class, Segmentation By Disease Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Psoriasis Biosimilars Market Regulatory and Investment Landscape
36. Psoriasis Biosimilars Market Competitive Landscape And Company Profiles
36.1. Psoriasis Biosimilars Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Psoriasis Biosimilars Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Psoriasis Biosimilars Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Fresenius Kabi AG Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
37. Psoriasis Biosimilars Market Other Major And Innovative Companies
